Target intelligence / Profile preview

Proteasome 26S subunit, non-ATPase 4 pseudogene 1 (PSMD4P1)

Target
PSMD4P1
Molecular classification
Pseudogene, Other
01

Overview

Proteasome 26S subunit, non-ATPase 4 pseudogene 1 (PSMD4P1) is classified as a pseudogene, meaning it is a genomic DNA sequence similar to a functional gene (in this case, PSMD4, a subunit of the 26S proteasome complex), but it is not capable of coding for a functional protein product[1][4][6]. Pseudogenes like PSMD4P1 may contain sequence elements of their parent gene but typically harbor disabling mutations such as frameshifts or premature stop codons, preventing normal protein expression. In general, PSMD4P1 is not a direct therapeutic target and does not encode a druggable protein or functional enzyme, receptor, or transporter[1][3][4][6]. Although rare pseudogenes may regulate their parent gene’s expression or have RNA-level functions, there is no evidence at present for such a role for PSMD4P1. Key critical notes: - The entry refers to a **pseudogene**, not a functional protein or canonical disease target[1][4][6]. - As a result, it does **not meet criteria for a typical therapeutic target** (no encoded receptor, enzyme, transporter, or druggable protein)[4][6]. - Inclusion as a therapeutic target is **incorrect**; this is a sequence artifact with potential (rare) regulatory roles, but not established for this pseudogene. Summary: - PSMD4P1 is not a real receptor, enzyme, or drug target; it is a noncoding **pseudogene** related to the PSMD4 proteasome subunit, and records explicitly list it as such[1][3][4]. - There are no known drugs, mechanisms of action, biomarker roles, or disease relevance specific to this pseudogene. - This entry should not be included among canonical molecular targets for drug discovery or therapeutic application.

Other names
PSMD4 pseudogene 1proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 pseudogene 1PSMD4P
02

Biological functions

While pseudogenes themselves may have regulatory roles via RNA mechanisms in some cases (such as acting as miRNA decoys or modulating mRNA stability[2][6]), PSMD4P1 itself is not known to have a direct documented functional biological role.
03

Disease associations

None specific for PSMD4P1; some pseudogenes have been implicated in disease through regulatory effects, but no such data is available for this entry[2][6].
04

Safety considerations

Pseudogenes can confound genetic studies (e.g., by interfering in PCR amplifications due to sequence similarity with real genes[6]), but there are no known safety concerns specific to PSMD4P1 in a therapeutic context.

Beyond the preview

Go deeper on Proteasome 26S subunit, non-ATPase 4 pseudogene 1 (PSMD4P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome 26S subunit, non-ATPase 4 pseudogene 1 (PSMD4P1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call